ENDV
Endonovo Therapeutics, Inc., a biotechnology company, develops, manufactures, and distributes non-invasive Electroceutical medical devices for regenerative medicine. The company offers SofPulse, a non-invasive Electroceutical therapeutic device for the palliative treatment of soft tissue injuries, chronic wounds, and post-operative pain and edema. Its Electroceuticals medical device is also used for the treatment of inflammation, wounds, cardiovascular diseases, chronic kidney diseases, liver diseases, non-alcoholic steatohepatitis, peripheral artery diseases, and ischemic stroke, as well as for central nervous system disorders, such as traumatic brain injury, acute concussions, post-concussion syndrome, and multiple sclerosis. Endonovo Therapeutics, Inc. was founded in 2008 and is based in Woodland Hills, California.
| Period | EPS | Revenue | FCF |
|---|---|---|---|
| 2025 Q2 | 0.00 | $0 | — |
| 2025 Q1 | -0.00 | $0 | — |
| 2024 Q4 | -0.00 | $0 | $102,760 |
| 2024 Q3 | -0.00 | $0 | -$1,110 |
| 2024 Q2 | -0.00 | $1,661 | $1,040 |
| 2024 Q1 | -0.00 | $8,382 | -$2,205 |
| 2023 Q4 | -0.01 | $5,982 | $526,233 |
| 2023 Q3 | -0.00 | $1,520 | -$65,367 |